Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences, Inc. (FBRX) Current Deferred Revenue (2016 - 2019)

Forte Biosciences (FBRX) has disclosed Current Deferred Revenue for 4 consecutive years, with $9000.0 as the latest value for Q3 2019.

  • On a quarterly basis, Current Deferred Revenue fell 75.0% to $9000.0 in Q3 2019 year-over-year; TTM through Sep 2019 was $9000.0, a 75.0% decrease, with the full-year FY2018 number at $36000.0, changed 0.0% from a year prior.
  • Current Deferred Revenue was $9000.0 for Q3 2019 at Forte Biosciences, down from $18000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $1.0 million in Q2 2018 to a low of $9000.0 in Q3 2019.
  • A 4-year average of $116833.3 and a median of $36000.0 in 2017 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: soared 2426.83% in 2018, then plummeted 98.26% in 2019.
  • Forte Biosciences' Current Deferred Revenue stood at $45000.0 in 2016, then fell by 20.0% to $36000.0 in 2017, then changed by 0.0% to $36000.0 in 2018, then plummeted by 75.0% to $9000.0 in 2019.
  • Per Business Quant, the three most recent readings for FBRX's Current Deferred Revenue are $9000.0 (Q3 2019), $18000.0 (Q2 2019), and $27000.0 (Q1 2019).